Ipsen’s partner Roche announces that Taspoglutide meets its primary endpoints in head-to-head study with sitagliptin (Januvia®) and versus placebo (Press release issued by Ipsen)
FDA Rejects Merck KGaA’s NDA for MS Treatment (FDA News)
Building A Better Patient Registry: Keep It Simple, But Let It Be Big (The Pink Sheet)
This is copyright protected information, to receive the full article, please click here to sign up and register.
SUBSCRIBE